Sentinel Oncology Limited

no public description

Glioblastoma multiforme (GBM) is one of the most common forms of brain cancer and is currently very poorly treated. Most patients have an average survival of less than 15 months and the five-year survival prognosis is less than 5%. The most recent new drug approved for the treatment of GBM was temozolomide, approved in 2005. There is a clear unmet need fo...

There are no effective treatments for Alzheimer’s disease. The incidence and health care costs of treating dementia are set to increase in the coming decades and there is an overwhelming need for effective treatments. Sentinel Oncology Limited (SOL) has developed a new class of drug molecules that have the potential to treat Alzheimer’s Disease. These new...

FXSFIX will deliver a diagnostic biomarker for use with SOL101, a clinical candidate drug for the treatment of Fragile X Syndrome (FXS). SOL101 is a first in class drug for FXS which is an orphan disease with no current clinically available treatments. SOL101 is an inhibitor of p70 S6 kinase 1 (S6K1), a protein recently shown to have utility in the contro...

Fragile X Syndrome is the single largest cause of genetically inherited disability amongst diseases categorised within the autism spectrum disorders. This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which will treat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstrated proof o...

There is a continuing need for new and more effective medicines to treat cancer patients. Despite a steady increase in the number of clinical treatment options available to patients, the number of people being diagnosed with cancer is growing. Sentinel Oncology is a company dedicated to the design and development of new and innovative approaches for the t...

There is a continuing need for new and more effective medicines to treat cancer patients. Despite a steady increase in the number of clinical treatment options available to patients, the number of people being diagnosed with cancer is growing with each passing year and resistence to current therapies is becoming a concerning issue to clinicians. Sentinel ...

Glioblastoma is a cancer of the brain which, although relatively rare, has a very poor survival rate. It is particularly deadly in young patients and overall survival for all patient groups over 5 years is less than 3%. One reason for the poor prognosis and survival rate is that the available treatments have progressed very little over the past 30 years, ...

Awaiting Public Project Summary